| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
|
Vasu, Sumithira
|
|
|
|
4 |
p. 1342-1349
|
artikel
|
| 2 |
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
|
Clark, Richard E.
|
|
|
|
4 |
p. 1102-1109
|
artikel
|
| 3 |
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
|
Löwenberg, Bob
|
|
|
|
4 |
p. 1110-1121
|
artikel
|
| 4 |
A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients
|
Wang, Yu-Hung
|
|
|
|
4 |
p. 644-654
|
artikel
|
| 5 |
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
|
Saygin, Caner
|
|
|
|
4 |
p. 549-554
|
artikel
|
| 6 |
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
|
Grunwald, Michael R.
|
|
|
|
4 |
p. 975-983
|
artikel
|
| 7 |
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
|
Lyman, Gary H.
|
|
|
|
4 |
p. 927-974
|
artikel
|
| 8 |
A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML
|
Zhang, Zhibo
|
|
|
|
4 |
p. 889-894
|
artikel
|
| 9 |
Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266-6274.
|
|
|
|
|
4 |
p. 829-831
|
artikel
|
| 10 |
Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
|
Banerjee, Rahul
|
|
|
|
4 |
p. 895-898
|
artikel
|
| 11 |
Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper
|
Neuendorff, Nina Rosa
|
|
|
|
4 |
p. 762-775
|
artikel
|
| 12 |
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers
|
Lu, Genmin
|
|
|
|
4 |
p. 728-739
|
artikel
|
| 13 |
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia
|
Cahill, Kirk E.
|
|
|
|
4 |
p. 599-606
|
artikel
|
| 14 |
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
|
Short, Nicholas J.
|
|
|
|
4 |
p. 909-915
|
artikel
|
| 15 |
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
|
Phillips, Tycel J.
|
|
|
|
4 |
p. 867-877
|
artikel
|
| 16 |
A practical approach to evaluating postoperative thrombocytopenia
|
Skeith, Leslie
|
|
|
|
4 |
p. 776-783
|
artikel
|
| 17 |
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial
|
Ohmachi, Ken
|
|
|
|
4 |
p. 984-993
|
artikel
|
| 18 |
A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help
|
Curran, Kevin J.
|
|
|
|
4 |
p. 1053-1061
|
artikel
|
| 19 |
A role for IL-34 in osteolytic disease of multiple myeloma
|
Baghdadi, Muhammad
|
|
|
|
4 |
p. 541-551
|
artikel
|
| 20 |
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
|
Gerds, Aaron T.
|
|
|
|
4 |
p. 1152-1161
|
artikel
|
| 21 |
A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation
|
de Laat-Kremers, Romy M. W.
|
|
|
|
4 |
p. 936-946
|
artikel
|
| 22 |
Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia
|
Morimoto, Yuki
|
|
|
|
4 |
p. 1100-1114
|
artikel
|
| 23 |
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
|
Hunter, Anthony M.
|
|
|
|
4 |
p. 1017-1028
|
artikel
|
| 24 |
Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI
|
Khorana, Alok A.
|
|
|
|
4 |
p. 1212-1221
|
artikel
|
| 25 |
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
|
Bassand, Jean-Pierre
|
|
|
|
4 |
p. 1081-1091
|
artikel
|
| 26 |
Bridging therapy before axi-cel for lymphoma
|
Belbachir, Safia
|
|
|
|
4 |
p. 1051-1052
|
artikel
|
| 27 |
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
|
Jain, Michael D.
|
|
|
|
4 |
p. 1042-1050
|
artikel
|
| 28 |
Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission
|
Sukumar, Senthil
|
|
|
|
4 |
p. 1264-1270
|
artikel
|
| 29 |
Cells of adult T-cell leukemia evade HTLV-1 Tax/NF-κB hyperactivation–induced senescence
|
Shudofsky, Abigail M. Druck
|
|
|
|
4 |
p. 564-569
|
artikel
|
| 30 |
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
|
Lyski, Zoe L.
|
|
|
|
4 |
p. 1207-1211
|
artikel
|
| 31 |
Central nervous system–restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation
|
Li, Hojun
|
|
|
|
4 |
p. 503-507
|
artikel
|
| 32 |
Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML
|
Mareschal, Sylvain
|
|
|
|
4 |
p. 1003-1016
|
artikel
|
| 33 |
Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients
|
Mohyuddin, Ghulam Rehman
|
|
|
|
4 |
p. 1097-1101
|
artikel
|
| 34 |
Choosing the right mouse model: comparison of humanized NSG and NBSGW mice for in vivo HSC gene therapy
|
Choo, Seunga
|
|
|
|
4 |
p. 916-926
|
artikel
|
| 35 |
Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients
|
Yan, Melissa
|
|
|
|
4 |
p. 1050-1058
|
artikel
|
| 36 |
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
|
Kemps, Paul G.
|
|
|
|
4 |
p. 664-679
|
artikel
|
| 37 |
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
|
Rijneveld, Anita W.
|
|
|
|
4 |
p. 1115-1125
|
artikel
|
| 38 |
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801
|
Marcucci, Guido
|
|
|
|
4 |
p. 696-705
|
artikel
|
| 39 |
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia
|
Kovacsovics, Tibor J.
|
|
|
|
4 |
p. 381-389
|
artikel
|
| 40 |
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
|
Pennisi, Martina
|
|
|
|
4 |
p. 676-686
|
artikel
|
| 41 |
Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition
|
Moison, Céline
|
|
|
|
4 |
p. 552-563
|
artikel
|
| 42 |
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
|
Patel, Kishan K.
|
|
|
|
4 |
p. 994-1002
|
artikel
|
| 43 |
CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model
|
Neidemire-Colley, Lotus
|
|
|
|
4 |
p. 947-958
|
artikel
|
| 44 |
Daily light-and-darkness onset regulates mouse hematopoietic stem cells
|
Golan, Karin
|
|
|
|
4 |
p. 704
|
artikel
|
| 45 |
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN
|
Voorhees, Peter M.
|
|
|
|
4 |
p. 1092-1096
|
artikel
|
| 46 |
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
|
Elalfy, Mohsen S.
|
|
|
|
4 |
p. 611-619
|
artikel
|
| 47 |
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
|
Kwiatkowski, Janet L.
|
|
|
|
4 |
p. 1243-1254
|
artikel
|
| 48 |
Determinants of hematology-oncology trainees' postfellowship career pathways with a focus on nonmalignant hematology
|
Marshall, Ariela L.
|
|
|
|
4 |
p. 361-369
|
artikel
|
| 49 |
Disruption of stem cell niche–confined R-spondin 3 expression leads to impaired hematopoiesis
|
Kurtova, Antonina V.
|
|
|
|
4 |
p. 491-507
|
artikel
|
| 50 |
Dock8 regulates BCR signaling and activation of memory B cells via WASP and CD19
|
Sun, Xiaoyu
|
|
|
|
4 |
p. 401-413
|
artikel
|
| 51 |
Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment
|
Lai, Catherine
|
|
|
|
4 |
p. 529-532
|
artikel
|
| 52 |
Eculizumab for refractory thrombosis in antiphospholipid syndrome
|
Hussain, Habiba
|
|
|
|
4 |
p. 1271-1277
|
artikel
|
| 53 |
Editorial Board
|
|
|
|
|
4 |
p. i
|
artikel
|
| 54 |
Editorial Board
|
|
|
|
|
4 |
p. i
|
artikel
|
| 55 |
Editorial Board
|
|
|
|
|
4 |
p. i
|
artikel
|
| 56 |
Editorial Board
|
|
|
|
|
4 |
p. i
|
artikel
|
| 57 |
Editorial Board
|
|
|
|
|
4 |
p. i
|
artikel
|
| 58 |
Editorial Board
|
|
|
|
|
4 |
p. i
|
artikel
|
| 59 |
Editorial Board
|
|
|
|
|
4 |
p. i
|
artikel
|
| 60 |
Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
|
Lissitchkov, Toshko
|
|
|
|
4 |
p. 1089-1094
|
artikel
|
| 61 |
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
|
Girgis, Suzette
|
|
|
|
4 |
p. 644-648
|
artikel
|
| 62 |
ELMO1 deficiency enhances platelet function
|
Patel, Akruti
|
|
|
|
4 |
p. 575-587
|
artikel
|
| 63 |
Eltrombopag for use in children with immune thrombocytopenia
|
Kim, Taylor Olmsted
|
|
|
|
4 |
p. 454-461
|
artikel
|
| 64 |
Elucidating parasite and host-cell factors enabling Babesia infection in sickle red cells under hypoxic/hyperoxic conditions
|
Beri, Divya
|
|
|
|
4 |
p. 649-663
|
artikel
|
| 65 |
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress
|
Kikuchi, Jiro
|
|
|
|
4 |
p. 508-524
|
artikel
|
| 66 |
Estimation of eligibility for and response to CAR-T therapy in the United States
|
Haslam, Alyson
|
|
|
|
4 |
p. 1032-1036
|
artikel
|
| 67 |
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
|
Bataller, Alex
|
|
|
|
4 |
p. 1193-1206
|
artikel
|
| 68 |
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
|
Castellino, Alessia
|
|
|
|
4 |
p. 1350-1360
|
artikel
|
| 69 |
FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia
|
Ramanagoudr-Bhojappa, Ramanagouda
|
|
|
|
4 |
p. 899-908
|
artikel
|
| 70 |
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
|
Ahn, Inhye E.
|
|
|
|
4 |
p. 832-841
|
artikel
|
| 71 |
Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma
|
Polprasert, Chantana
|
|
|
|
4 |
p. 588-595
|
artikel
|
| 72 |
Front Matter
|
|
|
|
|
4 |
p. ii
|
artikel
|
| 73 |
FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity
|
Ettinger, Ruth A.
|
|
|
|
4 |
p. 309-322
|
artikel
|
| 74 |
Gata2 +9.5 enhancer regulates adult hematopoietic stem cell self-renewal and T-cell development
|
You, Xiaona
|
|
|
|
4 |
p. 1095-1099
|
artikel
|
| 75 |
Gene-edited pseudogene resurrection corrects p47phox-deficient chronic granulomatous disease
|
Merling, Randall K.
|
|
|
|
4 |
p. 270-278
|
artikel
|
| 76 |
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
|
Mazzara, Saveria
|
|
|
|
4 |
p. 630-643
|
artikel
|
| 77 |
Germline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia
|
Winer, Peleg
|
|
|
|
4 |
p. 672-675
|
artikel
|
| 78 |
Guidance on changing therapy choice in myelofibrosis
|
McLornan, Donal P.
|
|
|
|
4 |
p. 607-610
|
artikel
|
| 79 |
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
|
Delforge, Michel
|
|
|
|
4 |
p. 1309-1318
|
artikel
|
| 80 |
Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack
|
Espinoza, J. Luis
|
|
|
|
4 |
p. 390-400
|
artikel
|
| 81 |
Hematopoietic cell transplantation for a child with OSTM1 osteopetrosis
|
Overholt, Kathleen M.
|
|
|
|
4 |
p. 279-281
|
artikel
|
| 82 |
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
|
Gagelmann, Nico
|
|
|
|
4 |
p. 555-559
|
artikel
|
| 83 |
Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice
|
Jackson, Jacob T.
|
|
|
|
4 |
p. 347-360
|
artikel
|
| 84 |
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
|
Stefanski, Heather E.
|
|
|
|
4 |
p. 541-548
|
artikel
|
| 85 |
High level of fetal-globin reactivation by designed transcriptional activator-like effector
|
Zhan, Jun
|
|
|
|
4 |
p. 687-695
|
artikel
|
| 86 |
High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer
|
Stonestrom, Aaron J.
|
|
|
|
4 |
p. 846-856
|
artikel
|
| 87 |
High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy
|
Lee, Lynn H.
|
|
|
|
4 |
p. 717-727
|
artikel
|
| 88 |
HMGA2 promotes long-term engraftment and myeloerythroid differentiation of human hematopoietic stem and progenitor cells
|
Kumar, Praveen
|
|
|
|
4 |
p. 681-691
|
artikel
|
| 89 |
Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation
|
de Koning, Coco
|
|
|
|
4 |
p. 428-432
|
artikel
|
| 90 |
Hypoxia-inducible KDM3A addiction in multiple myeloma
|
Ikeda, Sho
|
|
|
|
4 |
p. 323-334
|
artikel
|
| 91 |
IκB kinase 2 is not essential for platelet activation
|
Salzmann, Manuel
|
|
|
|
4 |
p. 638-643
|
artikel
|
| 92 |
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort
|
Reda, Gianluigi
|
|
|
|
4 |
p. 525-528
|
artikel
|
| 93 |
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial
|
Burke, G. A. Amos
|
|
|
|
4 |
p. 602-610
|
artikel
|
| 94 |
Immune cytopenia post–cord transplant in Hurler syndrome is a forme fruste of graft rejection
|
Deambrosis, David
|
|
|
|
4 |
p. 570-574
|
artikel
|
| 95 |
Impact of gender and caregiving responsibilities on academic success in hematology
|
King, Allison A.
|
|
|
|
4 |
p. 755-761
|
artikel
|
| 96 |
Inhibition of contact-mediated activation of factor XI protects baboons against S aureus–induced organ damage and death
|
Silasi, Robert
|
|
|
|
4 |
p. 658-669
|
artikel
|
| 97 |
Inhibition of the IRE-1α/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice
|
Schutt, Steven D.
|
|
|
|
4 |
p. 414-427
|
artikel
|
| 98 |
Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients
|
Zinter, Matt S.
|
|
|
|
4 |
p. 1002-1017
|
artikel
|
| 99 |
Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis
|
Rainone, Michael
|
|
|
|
4 |
p. 533-536
|
artikel
|
| 100 |
In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis
|
Zhang, Yanyan
|
|
|
|
4 |
p. 633-643
|
artikel
|
| 101 |
In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice
|
Li, Chang
|
|
|
|
4 |
p. 1122-1135
|
artikel
|
| 102 |
Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
|
Brem, Elizabeth A.
|
|
|
|
4 |
p. 1361-1364
|
artikel
|
| 103 |
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
|
Seymour, John F.
|
|
|
|
4 |
p. 1365-1370
|
artikel
|
| 104 |
Jeong H, Cho H, Kim H, et al. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis. Blood Adv. 2021;5(8):2142-2152.
|
|
|
|
|
4 |
p. 560
|
artikel
|
| 105 |
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation
|
Weisdorf, Daniel
|
|
|
|
4 |
p. 740-754
|
artikel
|
| 106 |
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
|
Herling, Marco
|
|
|
|
4 |
p. 842-845
|
artikel
|
| 107 |
Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation
|
Davis, Zachary
|
|
|
|
4 |
p. 1069-1080
|
artikel
|
| 108 |
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel
|
Sharma, Deva
|
|
|
|
4 |
p. 1018-1029
|
artikel
|
| 109 |
Maybe you can’t drive this CAR?
|
Derman, Benjamin A.
|
|
|
|
4 |
p. 1030-1031
|
artikel
|
| 110 |
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis
|
Stone, Richard M.
|
|
|
|
4 |
p. 444-453
|
artikel
|
| 111 |
Momelotinib is a highly potent inhibitor of FLT3-mutant AML
|
Azhar, Mohammad
|
|
|
|
4 |
p. 1186-1192
|
artikel
|
| 112 |
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study
|
Pagani, Chiara
|
|
|
|
4 |
p. 968-977
|
artikel
|
| 113 |
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy
|
Mastaglio, Sara
|
|
|
|
4 |
p. 335-346
|
artikel
|
| 114 |
Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice
|
Huang, Lulu
|
|
|
|
4 |
p. 991-1001
|
artikel
|
| 115 |
Ontogeny of platelet function
|
Margraf, Andreas
|
|
|
|
4 |
p. 692-703
|
artikel
|
| 116 |
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome
|
Mabrey, Frances Linzee
|
|
|
|
4 |
p. 611-616
|
artikel
|
| 117 |
Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.
|
|
|
|
|
4 |
p. 1136
|
artikel
|
| 118 |
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
|
Maziarz, Richard T.
|
|
|
|
4 |
p. 629-637
|
artikel
|
| 119 |
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature
|
Alimam, Samah
|
|
|
|
4 |
p. 1059-1068
|
artikel
|
| 120 |
PD-L1 and tumor-associated macrophages in de novo DLBCL
|
McCord, Ronald
|
|
|
|
4 |
p. 531-540
|
artikel
|
| 121 |
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
|
Gregory, Gareth P.
|
|
|
|
4 |
p. 1232-1242
|
artikel
|
| 122 |
Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma
|
Edwards, Camille V.
|
|
|
|
4 |
p. 482-490
|
artikel
|
| 123 |
Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion
|
Rius, Bibiana
|
|
|
|
4 |
p. 1037-1049
|
artikel
|
| 124 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
|
Mark, Tomer M.
|
|
|
|
4 |
p. 603-611
|
artikel
|
| 125 |
Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation
|
Itamura, Hidekazu
|
|
|
|
4 |
p. 667-671
|
artikel
|
| 126 |
Platelet respiration
|
Kholmukhamedov, Andaleb
|
|
|
|
4 |
p. 599-602
|
artikel
|
| 127 |
Platelet-targeted thrombolysis for treatment of acute ischemic stroke
|
Palazzolo, Jason S.
|
|
|
|
4 |
p. 561-574
|
artikel
|
| 128 |
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
|
Tam, Constantine S.
|
|
|
|
4 |
p. 1296-1308
|
artikel
|
| 129 |
Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera
|
Pouw, Richard B.
|
|
|
|
4 |
p. 621-632
|
artikel
|
| 130 |
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
|
Garcia-Manero, Guillermo
|
|
|
|
4 |
p. 508-518
|
artikel
|
| 131 |
Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
|
Kuczmarski, Thomas M.
|
|
|
|
4 |
p. 1126-1136
|
artikel
|
| 132 |
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
|
Lamble, Adam J.
|
|
|
|
4 |
p. 575-585
|
artikel
|
| 133 |
Presentation of BK polyomavirus–associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation
|
Imlay, Hannah
|
|
|
|
4 |
p. 617-628
|
artikel
|
| 134 |
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
|
Voorhees, Timothy J.
|
|
|
|
4 |
p. 1255-1263
|
artikel
|
| 135 |
Prognostic restaging after treatment initiation in patients with AL amyloidosis
|
Abdallah, Nadine
|
|
|
|
4 |
p. 1029-1036
|
artikel
|
| 136 |
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
|
Bataller, Alex
|
|
|
|
4 |
p. 927-935
|
artikel
|
| 137 |
Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR
|
Murray, Duncan
|
|
|
|
4 |
p. 519-530
|
artikel
|
| 138 |
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
|
Drillet, Gaëlle
|
|
|
|
4 |
p. 537-540
|
artikel
|
| 139 |
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
|
Garcia, Jacqueline S.
|
|
|
|
4 |
p. 978-990
|
artikel
|
| 140 |
Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi
|
Painschab, Matthew S.
|
|
|
|
4 |
p. 612-620
|
artikel
|
| 141 |
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide
|
Kasamon, Yvette L.
|
|
|
|
4 |
p. 288-292
|
artikel
|
| 142 |
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
|
Costa, Luciano J.
|
|
|
|
4 |
p. 282-287
|
artikel
|
| 143 |
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
|
Gagelmann, Nico
|
|
|
|
4 |
p. 1222-1231
|
artikel
|
| 144 |
Reduced red blood cell deformability in Plasmodium knowlesi malaria
|
Barber, Bridget E.
|
|
|
|
4 |
p. 433-443
|
artikel
|
| 145 |
Resistance mechanism for ibrutinib in marginal zone lymphoma
|
Epperla, Narendranath
|
|
|
|
4 |
p. 500-502
|
artikel
|
| 146 |
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
|
Bhattacharya, Romit
|
|
|
|
4 |
p. 959-967
|
artikel
|
| 147 |
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs
|
Prosty, Connor
|
|
|
|
4 |
p. 857-866
|
artikel
|
| 148 |
RNA-regulatory exosome complex suppresses an apoptotic program to confer erythroid progenitor cell survival in vivo
|
Fraga de Andrade, Isabela
|
|
|
|
4 |
p. 586-601
|
artikel
|
| 149 |
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
|
Nastoupil, Loretta J.
|
|
|
|
4 |
p. 1143-1151
|
artikel
|
| 150 |
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
|
Shotton, Rohan
|
|
|
|
4 |
p. 878-888
|
artikel
|
| 151 |
Stem cell donors should be screened for CHIP
|
DeZern, Amy E.
|
|
|
|
4 |
p. 784-788
|
artikel
|
| 152 |
Stem cell donors should not be screened for clonal hematopoiesis
|
Gibson, Christopher J.
|
|
|
|
4 |
p. 789-792
|
artikel
|
| 153 |
Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion–associated myeloid neoplasm
|
Miltiadous, Oriana
|
|
|
|
4 |
p. 1137-1142
|
artikel
|
| 154 |
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
|
Heynen, Guus J. J. E.
|
|
|
|
4 |
p. 469-481
|
artikel
|
| 155 |
Survival in Agent Orange exposed and unexposed Vietnam-era veterans who were diagnosed with lymphoid malignancies
|
Ma, Helen
|
|
|
|
4 |
p. 1037-1041
|
artikel
|
| 156 |
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
|
Lasho, Terra L.
|
|
|
|
4 |
p. 370-380
|
artikel
|
| 157 |
The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis
|
Naymagon, Leonard
|
|
|
|
4 |
p. 655-666
|
artikel
|
| 158 |
The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia
|
Yeshurun, Moshe
|
|
|
|
4 |
p. 670-680
|
artikel
|
| 159 |
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
|
Mascarenhas, John
|
|
|
|
4 |
p. 1162-1174
|
artikel
|
| 160 |
The nuclear receptor corepressor NCoR1 regulates hematopoiesis and leukemogenesis in vivo
|
Wan, Xiaoling
|
|
|
|
4 |
p. 644-657
|
artikel
|
| 161 |
The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
|
Male, Christoph
|
|
|
|
4 |
p. 620-629
|
artikel
|
| 162 |
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
|
Martínez-Cuadrón, David
|
|
|
|
4 |
p. 1278-1295
|
artikel
|
| 163 |
T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity
|
Lum, Su Han
|
|
|
|
4 |
p. 1319-1328
|
artikel
|
| 164 |
Unrelated donor α/β T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia
|
Leahy, Allison Barz
|
|
|
|
4 |
p. 1175-1185
|
artikel
|
| 165 |
Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield
|
Farhadfar, Nosha
|
|
|
|
4 |
p. 706-716
|
artikel
|
| 166 |
What the 2018 ASH venous thromboembolism guidelines omitted: nonadministration of pharmacologic prophylaxis in hospitalized patients
|
Owodunni, Oluwafemi P.
|
|
|
|
4 |
p. 596-598
|
artikel
|
| 167 |
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
|
Tran, Thai Hoa
|
|
|
|
4 |
p. 1329-1341
|
artikel
|
Tijdschrift beschrijving